John Rajapakse, MD
Internal Medicine · Perth Amboy, NJNPI 1639377914
Payments from drug & device makers
Across 503 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$766
- Lilly USA, LLC$712
- GSK$631
- Novo Nordisk$616
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,377100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 100 | $1,802 |
| AbbVie(2 entities) | 58 | $1,292 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 59 | $766 |
| Lilly USA, LLC | 56 | $712 |
| GSK | 27 | $631 |
| Novo Nordisk | 45 | $616 |
| Pfizer | 34 | $550 |
| Boehringer Ingelheim | 27 | $365 |
| Merck | 21 | $280 |
| Amgen | 13 | $194 |
| Exact Sciences | 12 | $189 |
| Sanofi-aventis U.S. LLC | 4 | $186 |
| Axsome Therapeutics, Inc. | 3 | $148 |
| Idorsia Pharmaceuticals US Inc | 8 | $124 |
| Biodelivery Sciences International, Inc. | 4 | $52 |
| Astellas Pharma US Inc | 3 | $45 |
| Abbott | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Novartis | 3 | $38 |
| Amarin Pharma, Inc. | 3 | $36 |
| Ardelyx, Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| IBSA Pharma Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Eisai Inc. | 2 | $26 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Renalytix AI, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$502
- QULIPTA$464
- TRELEGY ELLIPTA$250
- Symbravo$125
How this compares
$8,383 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 162 | $88,152 |
| FarxigaDapagliflozin Propanediol | 147 | $82,823 |
| OzempicSemaglutide | 61 | $69,153 |
| TrulicityDulaglutide | 63 | $62,324 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $52,358 |
| EliquisApixaban | 140 | $48,501 |
| JanuviaSitagliptin Phosphate | 78 | $41,509 |
| MounjaroTirzepatide | 25 | $26,497 |
| Bydureon BciseExenatide Microspheres | 49 | $26,129 |
| LinzessLinaclotide | 45 | $25,220 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $19,327 |
| TradjentaLinagliptin | 28 | $18,299 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $16,769 |
| Lactulose | 103 | $12,746 |
| JanumetSitagliptin Phos/Metformin Hcl | 38 | $11,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $365 | $106,451190 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,802 | $91,568162 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $631 | $91,052175 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $712 | $88,82188 claims |
| Novo NordiskOzempic | $616 | $69,15361 claims |
| MerckJanuvia, Janumet | $280 | $53,250116 claims |
| PfizerEliquis, Lipitor | $550 | $52,886152 claims |
| AbbVieLinzess | $1,292 | $25,22045 claims |
| NovartisEntresto | $38 | $9,21314 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $5,61615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Perth Amboy
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.